Richard E. Uihlein
CIK: 0001694903
Associated companies
Transaction History
| GALT | ▲ Buy | Option Exercise | 31,825,235 | $95.5M | 7/31/2026 | View on chart |
| GALT | ▲ Buy | Option Exercise | 2,550,932 | $10.3M | 7/31/2026 | View on chart |
| GALT | ▲ Buy | Grant | 13,158 | $40K | 1/16/2026 | View on chart |
| GALT | ▲ Buy | Grant | 32,520 | $40K | 1/23/2025 | View on chart |
| GALT | ▲ Buy | Grant | 23,256 | $40K | 1/24/2024 | View on chart |
| GALT | ▲ Buy | Option Exercise | 200,000 | $600K | 9/26/2023 | View on chart |
| GALT | ▲ Buy | Option Exercise | 1,466,204 | $7.3M | 9/26/2023 | View on chart |
| GALT | ▲ Buy | Option Exercise | 170,000 | $850K | 9/26/2023 | View on chart |
| GALT | ▲ Buy | Option Exercise | 200,000 | $600K | 9/26/2023 | View on chart |
| GALT | ▲ Buy | Option Exercise | 200,000 | $652K | 9/26/2023 | View on chart |
| GALT | ▲ Buy | Grant | 36,036 | $40K | 1/26/2023 | View on chart |
| GALT | ▲ Buy | Grant | 17,677 | $35K | 1/24/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Galectin Clears Balance Sheet with $105M Debt Conversion
Galectin Therapeutics announced that a $105 million debt conversion has removed its outstanding debt, improving its balance sheet. The company still needs to secure a Phase 3 partnership to move its lead product forward. The move may reduce financial risk but the next milestone remains critical for the company's progress.
Galectin Clears Balance Sheet with $105M Debt Conversion. Galectin Therapeutics announced that a $105 million debt conversion has removed its outstanding debt, improving its balance sheet. The company still needs to secure a Phase 3 partnership to move its lead product forward. The move may reduce financial risk but the next milestone remains critical for the company's progress.